BONE BIOLOGICS CORPORATION
Income Statement
| Line Item | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | $1.07B | $1.07B |
| Cost of Revenue | — | — | — | — | — | — | — | — |
| Gross Profit | — | — | — | — | — | — | — | — |
| Gross Margin | — | — | — | — | — | — | — | — |
| Operating Expenses | ||||||||
| Research & Development | — | $1.1M | $2.1M | $6.9M | $1.6M | $82.0K | $340.7K | $1.1M |
| SG&A Expense | — | $2.2M | $2.1M | $2.5M | $2.1M | $1.0M | $484.3K | $1.4M |
| Operating Income | — | $-3.2M | $-4.2M | $-9.4M | $-3.7M | $-1.1M | $-825.0K | $-2.4M |
| Operating Margin | — | — | — | — | — | — | -0.1% | -0.2% |
| Interest Expense | — | — | — | — | — | — | — | — |
| Pretax Income | — | — | — | — | — | $-1.6M | $-1.8M | $-3.4M |
| Income Tax Expense | — | — | — | — | — | $1.6K | $1.6K | $1.6K |
| Net Income | — | $-3.1M | $-4.1M | $-8.9M | $-1.5M | $-1.6M | $-1.8M | $-3.4M |
| Net Margin | — | — | — | — | — | — | -0.2% | -0.3% |
| EPS (Basic) | — | $-2.65 | $-5.79 | $-6.80 | $-1.04 | $-0.01 | $-0.02 | $-0.02 |
| EPS (Diluted) | — | $-2.65 | $-5.79 | $-6.80 | $-1.04 | $-0.01 | $-0.02 | $-0.02 |
| Shares Outstanding (Basic) | 1.8M | 1.2M | 1.3M | 1.3M | 1.4M | 310.5M | 368.2M | 920.5M |
| Shares Outstanding (Diluted) | 1.8M | 1.2M | 1.3M | 1.3M | 1.4M | 310.5M | 368.2M | 920.5M |
| Dividends Per Share | — | — | — | — | — | — | — | — |